Therapeutic area intelligence for PD-1 Inhibition with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Merck →

Assets

KEYTRUDA →

Recent signals(1)

ClinicalJuly 17, 2026

KEYTRUDA Shows Significant PFS Improvement in dMMR Endometrial Cancer in Phase 3 Trial

KEYTRUDA (pembrolizumab) improved progression-free survival compared to platinum doublet chemotherapy in dMMR endometrial cancer patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.